Editas Medicine

Editas to lay off staff after search for sickle cell partner comes up empty
BioPharma Dive
Thu, 12/12/24 - 11:52 pm
Editas Medicine
sickle cell disease
layoffs
reni-cel
Editas, changing course again, looks to partner lead CRISPR therapy
BioPharma Dive
Tue, 10/22/24 - 11:45 am
Editas Medicine
gene editing
CRISPR
reni-cel
sickle cell disease
beta thalassemia
Editas cashes in on portion of Vertex gene editing licensing agreement for $57M
Fierce Biotech
Fri, 10/4/24 - 09:24 am
Editas Medicine
Cas9
patents
Vertex Pharmaceuticals
gene editing
Could Editas Medicine Become the Next CRISPR Therapeutics?
Motley Fool
Sun, 01/21/24 - 05:01 pm
Editas Medicine
gene editing
CRISPR Therapeutics
Editas and Vertex Ink Deal for Cas9 License for $50M Upfront
BioSpace
Wed, 12/13/23 - 10:07 pm
Editas Medicine
Vertex Pharmaceuticals
Cas9
Casgevy
ASH23: Pharma branding, Editas’ high bar and clinical trial diversity
BioPharma Dive
Mon, 12/11/23 - 10:52 pm
ASH 2023
JNJ
Editas Medicine
cliincal trials
Gene Editing Race Between Editas and Vertex, CRISPR Heats Up
BioSpace
Mon, 06/12/23 - 09:58 am
gene editing
Editas Medicine
Vertex Pharmaceuticals
CRISPR Therapeutics
EDIT-301
sickle cell disease
beta thalassemia
Gene Editing Therapeutics Could Hit the Market in 2023
BioSpace
Mon, 04/10/23 - 11:32 am
gene editing
CRISPR Therapeutics
Vertex Pharmaceuticals
Intellia Therapeutics
Editas Medicine
Beam Therapeutics
Major readouts on the horizon for small developers
EP Vantage
Fri, 03/31/23 - 10:19 am
Aldeyra Therapeutics
Autolus Therapeutics
Bavarian Nordic
BioXcel Therapeutics
Disc Medicine
Editas Medicine
Immunogen
Lantheus
Mersana Therapeutics
NGM Biopharmaceuticals
Omeros
Roche
Sutro BioPharma
uniQure
Valneva
Viking Therapeutics
BioSpace Layoff Tracker 2023: Grifols, Frequency, Eliem and More Cut Staff
BioSpace
Thu, 02/16/23 - 11:18 am
layoffs
Grifols
Frequency Therapeutics
Eliem Therapeutics
Aligos Therapeutics
Thermo Fisher Scientific
Magenta Therapeutics
Eisai
Amgen
Y-mAbs Therapeutics
Century Therapeutics
Elevation Oncology
Calithera Biosciences
Editas Medicine
Verily
Abzena
Editas, in next restructuring step, to sell cell therapy work to Shoreline
BioPharma Dive
Thu, 01/19/23 - 07:43 pm
Editas Medicine
natural killer cell therapy
Shoreline Biosciences
Editas finds buyer for iNK programs 10 days after clearing out pipeline
Fierce Biotech
Thu, 01/19/23 - 10:48 am
Editas Medicine
iNK
Shoreline Biosciences
Editas edits pipeline, lays off 20% and says bye to CSO to kick off #JPM23 
Endpoints
Mon, 01/9/23 - 10:32 am
JPMHC 2023
Editas Medicine
layoffs
Editas teases tiny sickle cell sample in effort to climb back into gene editing's upper echelon
Fierce Biotech
Tue, 12/6/22 - 10:34 am
Editas Medicine
sickle cell disease
gene editing
EDT-301
Where Will Editas Medicine Be in 1 Year?
Motley Fool
Sun, 11/20/22 - 12:52 pm
Editas Medicine
EDIT-101
Leber's congenital amaurosis
Editas halts lead CRISPR program after efficacy data underwhelm
Endpoints
Thu, 11/17/22 - 12:10 pm
Editas Medicine
CRISPR
EDIT-101
clinical trials
ASH preview – waiting for Editas
EP Vantage
Wed, 11/9/22 - 10:40 am
ASH 2022
sickle cell disease
Bluebird Bio
Sangamo BioSciences
Novartis
Editas Medicine
gene therapy
Vertex Pharmaceuticals
Sanofi
Editas Awaits Data to Determine the Future of Ophthalmic Gene Therapy, EDIT-101
BioSpace
Wed, 11/2/22 - 10:54 pm
Editas Medicine
EDIT-101
gene therapy
Leber's congenital amaurosis
Editas Rumored to be in “Advanced Discussions” around Potential Sale of Oncology Assets
BioSpace
Tue, 10/18/22 - 10:13 pm
Editas Medicine
gene editing
CRISPR
M&A
oncology
Editas treats first patient in sickle cell trial as FDA lifts partial hold
BioPharma Dive
Fri, 07/29/22 - 10:03 am
Editas Medicine
clinical trials
CRISPR
gene editing
sickle cell disease

Pages